Berubicin, a new drug being developed for the treatment of glioblastoma, may be able to actually access and treat glioblastoma cells in the brain, according to the drug's manufacturer.
The drug - which belongs to a class of powerful anthracyclines - is the first of its kind to cross the blood-brain barrier and attack brain tumors directly in clinical testing. In phase 1 clinical trials, 44 percent of patients showed significant anti-tumor activity, according to a CNS Pharmaceuticals press release.
Glioblastoma - a highly invasive brain tumor with limited response to current therapy - is...
The comment you're trying to see no longer exists.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.